Discovery of a novel dual functional phenylpyrazole-styryl hybrid that induces apoptotic and autophagic cell death in bladder cancer cells.

[1]  P. A. Valiente,et al.  gmx_MMPBSA: A New Tool to Perform End-State Free Energy Calculations with GROMACS. , 2021, Journal of chemical theory and computation.

[2]  J. Freeman,et al.  Use of Zebrafish in Drug Discovery Toxicology. , 2020, Chemical research in toxicology.

[3]  J. Castracane,et al.  A Dynamic Culture Method to Produce Ovarian Cancer Spheroids under Physiologically-Relevant Shear Stress , 2018, Cells.

[4]  F. Abas,et al.  Asymmetrical meta-methoxylated diarylpentanoids: Rational design, synthesis and anti-cancer evaluation in-vitro. , 2018, European journal of medicinal chemistry.

[5]  A. Nudelman,et al.  Synthesis and Biological Evaluation of Derivatives of Indoline as Highly Potent Antioxidant and Anti-inflammatory Agents. , 2018, Journal of medicinal chemistry.

[6]  David Lagorce,et al.  FAF‐Drugs4: free ADME‐tox filtering computations for chemical biology and early stages drug discovery , 2017, Bioinform..

[7]  Min Wang,et al.  Design, synthesis and antitumor activity of Novel Sorafenib derivatives bearing pyrazole scaffold. , 2017, Bioorganic & medicinal chemistry.

[8]  X. Bian,et al.  Autophagy-induced KDR/VEGFR-2 activation promotes the formation of vasculogenic mimicry by glioma stem cells , 2017, Autophagy.

[9]  Ying Zhang,et al.  Design, synthesis and biological evaluation of novel EGFR/HER2 dual inhibitors bearing a oxazolo[4,5-g]quinazolin-2(1H)-one scaffold. , 2016, European journal of medicinal chemistry.

[10]  M. Chatzinikolaidou.  Cell spheroids: the new frontiers in in vitro models for cancer drug validation. , 2016, Drug discovery today.

[11]  M. Lawler,et al.  Overcoming Resistance to Targeted Therapies in Cancer. , 2015, Seminars in oncology.

[12]  T. Yamanaka,et al.  Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial. , 2015, The Lancet. Oncology.

[13]  David Gilligan,et al.  Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer. , 2015, The Lancet. Oncology.

[14]  Berk Hess,et al.  GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers , 2015 .

[15]  J. Irwin,et al.  An Aggregation Advisor for Ligand Discovery. , 2015, Journal of medicinal chemistry.

[16]  H. Christofk,et al.  Autocrine VEGF maintains endothelial survival through regulation of metabolism and autophagy , 2015, Journal of Cell Science.

[17]  P. Jänne,et al.  AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. , 2015, The New England journal of medicine.

[18]  F. Abas,et al.  Synthesis and Sar Study of Diarylpentanoid Analogues as New Anti-Inflammatory Agents , 2014, Molecules.

[19]  Simon C Watkins,et al.  A Complex between Atg7 and Caspase-9 , 2013, The Journal of Biological Chemistry.

[20]  A. Abadi,et al.  Synthesis and in vitro antiproliferative effect of novel quinoline-based potential anticancer agents. , 2013, European journal of medicinal chemistry.

[21]  Steven P Jones,et al.  PDGF-mediated autophagy regulates vascular smooth muscle cell phenotype and resistance to oxidative stress. , 2013, The Biochemical journal.

[22]  D. Tindall,et al.  Autophagy control by the VEGF-C/NRP-2 axis in cancer and its implication for treatment resistance. , 2013, Cancer research.

[23]  D. Nguyen,et al.  TRAIL induces autophagic protein cleavage through caspase activation in melanoma cell lines under arginine deprivation , 2013, Molecular and Cellular Biochemistry.

[24]  D. Gozuacik,et al.  Cleavage of Atg3 protein by caspase-8 regulates autophagy during receptor-activated cell death , 2012, Apoptosis.

[25]  O. Prakash,et al.  Design, synthesis, computational and biological evaluation of some new hydrazino derivatives of DHA and pyranopyrazoles. , 2012, European journal of medicinal chemistry.

[26]  S. Ashton,et al.  Discovery of AZD2932, a new Quinazoline Ether Inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases. , 2012, Bioorganic & medicinal chemistry letters.

[27]  Yanmin Zhang,et al.  Antitumor Activity of Taspine by Modulating the EGFR Signaling Pathway of Erk1/2 and Akt In Vitro and In Vivo , 2011, Planta medica.

[28]  Luhua Lai,et al.  Discovery of dual target inhibitors against cyclooxygenases and leukotriene A4 hydrolyase. , 2011, Journal of medicinal chemistry.

[29]  Yuquan Wei,et al.  Synthesis and biological evaluation of novel 5-benzylidenethiazolidine-2,4-dione derivatives for the treatment of inflammatory diseases. , 2011, Journal of medicinal chemistry.

[30]  M. Hixon,et al.  Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism. , 2011, Biochemistry.

[31]  Jai-Sing Yang,et al.  Synthesis of 1-benzyl-3-(5-hydroxymethyl-2-furyl)selenolo[3,2-c]pyrazole derivatives as new anticancer agents. , 2010, European journal of medicinal chemistry.

[32]  B. Levine,et al.  The autophagy effector Beclin 1: a novel BH3-only protein , 2008, Oncogene.

[33]  J. Engelman,et al.  A sweet new role for EGFR in cancer. , 2008, Cancer cell.

[34]  A. Markoe,et al.  Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. , 2007, The New England journal of medicine.

[35]  Robert J. Gillies,et al.  Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells , 2005, Molecular Cancer Therapeutics.

[36]  G. Kirsch,et al.  New thiophene analogues of kenpaullone: synthesis and biological evaluation in breast cancer cells. , 2005, European journal of medicinal chemistry.

[37]  H. Varmus,et al.  Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.

[38]  A. Ullrich,et al.  The discovery of receptor tyrosine kinases: targets for cancer therapy , 2004, Nature Reviews Cancer.

[39]  Min Chen,et al.  Initiator caspases in apoptosis signaling pathways , 2002, Apoptosis.

[40]  M. Campiglio,et al.  Biologic and therapeutic role of HER2 in cancer , 2003, Oncogene.

[41]  T. Natsume,et al.  Mouse Apg16L, a novel WD-repeat protein, targets to the autophagic isolation membrane with the Apg12-Apg5 conjugate , 2003, Journal of Cell Science.

[42]  M. Komatsu,et al.  Human Apg3p/Aut1p Homologue Is an Authentic E2 Enzyme for Multiple Substrates, GATE-16, GABARAP, and MAP-LC3, and Facilitates the Conjugation of hApg12p to hApg5p* , 2002, The Journal of Biological Chemistry.

[43]  T. Ueno,et al.  The Human Homolog of Saccharomyces cerevisiae Apg7p Is a Protein-activating Enzyme for Multiple Substrates Including Human Apg12p, GATE-16, GABARAP, and MAP-LC3* , 2001, The Journal of Biological Chemistry.

[44]  J C Reed,et al.  Mechanisms of apoptosis. , 2000, The American journal of pathology.

[45]  Michael D. George,et al.  A protein conjugation system essential for autophagy , 1998, Nature.

[46]  J. Davie,et al.  In situ cross-linking by cisplatin of nuclear matrix-bound transcription factors to nuclear DNA of human breast cancer cells. , 1998, Cancer research.

[47]  G M Cohen,et al.  Caspases: the executioners of apoptosis. , 1997, The Biochemical journal.

[48]  H. Gurney,et al.  Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  M. Jordan,et al.  Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[50]  Philip R. Cohen,et al.  The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). , 1993, Cancer treatment reviews.

[51]  A. Einstein,et al.  Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. , 1987, JAMA.